The Mesoblast limited (ASX: MSB) share price has returned from its trading halt and crashed significantly lower.
In early trade the biotechnology company’s shares are down a massive 45% to $2.08.
Why is the Mesoblast share price crashing lower?
Investors have been selling the company’s shares this morning after it provided an update on the randomised controlled trial of its remestemcel-L product in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection.
According to the release, the Data Safety Monitoring Board (DSMB) has performed a third interim analysis on the trial’s first 180 patients.
The trial was aiming to achieve a primary endpoint of 43% reduction in mortality at 30 days for treatment with remestemcel-L on top of maximal care in a trial of 300 patients.
This target was based on pilot data observed during the initial stages of the pandemic when control mortality rates were exceedingly high. It was also prior to new evolving treatment regimens that have reduced disease mortality in ventilated patients.
While the DSMB has reported that there were no safety concerns, importantly, it noted that the trial is unlikely to meet the 30-day mortality reduction endpoint at the planned 300 patient enrolment.
In light of this, the DSMB has recommended that the trial be ended early at just 223 enrolled patients.
What now?
While the primary endpoint has not been achieved, management is pushing ahead to see if it achieves its secondary endpoints.
These include days alive off mechanical ventilation at 60 days post randomisation, overall survival, days in intensive care, duration of hospitalisation, and cardiac, neurological, and pulmonary organ damage.
What went wrong?
The company has suggested that changes in the treatment regimens for COVID-19 patients are to blame for the trial’s failure.
It explained: “During the course of the trial, as the pandemic has evolved, numerous changes in the treatment regimens for COVID-19 patients occurred, including both prior to and while on mechanical ventilation that may have an effect on the mortality endpoint in the trial.”
“These include extended management of patients prior to ventilator support, and use of experimental therapies such as dexamethasone, antivirals, and re-purposed immunomodulatory agents. All of these may have changed the natural course of ventilated patients and reduced overall mortality rates during the trial compared to the early stages of the pandemic,” it added.
What about the Novartis deal?
Readers may be aware that Mesoblast recently signed a deal with Novartis for remestemcel-L. That agreement will have an initial focus on the development of a treatment for acute respiratory distress syndrome (ARDS), including that associated with COVID-19.
It also sees Novartis pay US$50 million upfront and then upwards of US$1.25 billion in milestone payments.
This news appears to have led to concerns that this deal may now not go ahead.
Though, the release advises that “Mesoblast and Novartis will both analyse these results to identify meaningful clinical outcomes that may guide decisions on the development program for remestemcel-L in non-COVID ARDS.”
This Tiny ASX Stock Could Be the Next Afterpay
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting…
Because ‘Doc’ Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget ‘buy now pay later’, this stock could be the next hot stock on the ASX.
Doc and his team have published a detailed report on this tiny ASX stock. Find out how you can access what could be the NEXT Afterpay today!
See how you can find out the name of this stock
Returns as of 6th October 2020
More reading
- Why Mesoblast, Pilbara Minerals, Pushpay, & Retail Food Group shares are dropping lower
- ASX 200 down 0.1%: APRA removes bank dividend restrictions, Fortescue slides, Zip higher
- Why the Mesoblast (ASX:MSB) share price is sinking 11% lower
- These are 8 of the best performing ASX healthcare shares of 2020 so far
- Which shares will benefit from trillions of dollars in new global stimulus?
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
The post Why the Mesoblast (ASX:MSB) share price crashed 45% lower today appeared first on The Motley Fool Australia.
from The Motley Fool Australia https://ift.tt/2LLM0eW
Leave a Reply